Drug Discovery Stocks
Biotechnology and life sciences firms in this sector focus on the high-risk, high-reward phase of identifying and validating novel molecular targets to address unmet medical needs. These entities operate primarily through heavy R&D investment, navigating rigorous clinical trial milestones and regulatory hurdles that dictate valuation swings and long-term liquidity events.
As of Oct 23, 2026, Drug Discovery has 147 US-listed companies worth $1.7T combined. The median member moved +2.3% over the past week; IRON led among the 25 largest at +31.1% and ABCL trailed at +0.2%.
Companies in Drug Discovery
- LLY – Eli Lilly and Company, $1.1T
- PFE – Pfizer Inc, $171B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- RVMD – Revolution Medicines Inc, $40.2B
- INCY – Incyte Corporation, $23.7B
- RVTY – Revvity Inc., $17.7B
- CRL – Charles River Laboratories, $16.6B
- EXEL – Exelixis Inc, $16.2B
- ASND – Ascendis Pharma AS, $16B
- HALO – Halozyme Therapeutics Inc, $14.1B
- TWST – Twist Bioscience Corp, $9.9B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- LGND – Ligand Pharmaceuticals Incorporated, $6.1B
- ERAS – Erasca Inc, $5.1B
- TNGX – Tango Therapeutics Inc, $4.5B
- RLAY – Relay Therapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- ABCL – Abcellera Biologics Inc, $3.8B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- IDYA – Ideaya Biosciences Inc, $3.5B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- IRON – Disc Medicine Inc., $3B
- ELVN – Enliven Therapeutics Inc., $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- PHVS – Pharvaris BV, $2.1B
- IMNM – Immunome Inc, $2.1B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- SDGR – Schrodinger Inc, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- ABSI – Absci Corp, $1.5B
- AAPG – Ascentage Pharma Group International, $1.4B
- CERT – Certara Inc, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- ANRO – Alto Neuroscience, Inc., $956M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- HELP – Cybin Inc., $799M
- SGP – SpyGlass Pharma, Inc., $792M
- CTKB – Cytek Biosciences Inc, $763M
- DNA – Ginkgo Bioworks Holdings, $692M
- AURA – Aura Biosciences Inc, $678M
- OABI – OmniAb Inc., $663M
- ABUS – Arbutus Biopharma Corp, $648M
- DRUG – Bright Minds Biosciences Inc, $506M
- EVO – Evotec SE ADR, $478M
- ARVN – Arvinas Inc, $472M
- OCS – Oculis Holding AG Ordinary shares, $461M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- TECX – Tectonic Therapeutic, Inc., $444M
- OVID – Ovid Therapeutics Inc, $441M
- PRTA – Prothena Corporation plc, $435M
- ENTX – Entera Bio Ltd, $435M
- AVIR – Atea Pharmaceuticals Inc, $413M
- EIKN – Eikon Therapeutics, Inc. Common Stock, $408M
- TRXB – TRex Bio, Inc. Common stock, $384M
- SLP – Simulations Plus Inc, $374M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- CCCC – C4 Therapeutics Inc, $325M
- FULC – Fulcrum Therapeutics Inc, $279M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- PRLD – Prelude Therapeutics Inc, $258M
- ACIU – AC Immune Ltd, $256M
- IMRX – Immuneering Corp, $255M
- PALI – Palisade Bio Inc, $251M
- BCYC – Bicycle Therapeutics Ltd, $245M
- BIOA – BioAge Labs, Inc, $222M
- CGEN – Compugen, $219M
- CAMP – CAMP4 THERAPEUTICS CORPORATION, $215M
- SION – Sionna Therapeutics, Inc. Common Stock, $187M
- STRO – Sutro Biopharma, $181M
- ADAG – Adagene Inc, $165M
- CRDL – Cardiol Therapeutics Inc Class A, $146M
- CDXS – Codexis Inc, $145M
- ABOS – Acumen Pharmaceuticals Inc, $143M
- FHTX – Foghorn Therapeutics Inc, $110M
- MXCT – MaxCyte Inc, $104M
- VANI – Vivani Medical Inc., $104M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- AGPU – Axe Compute Inc., $96.2M
- KZIA – Kazia Therapeutics Ltd ADR, $89.7M
- CGTX – Cognition Therapeutics Inc, $89.1M
- TELO – Telomir Pharmaceuticals, Inc. Common Stock, $80.2M
- NTHI – NeOnc Technologies Holdings, Inc. Common Stock, $79.2M
- PMN – ProMIS Neurosciences Inc., $74.3M
- IBIO – iBio, Inc. Common Stock, $72.3M
- MAIA – MAIA Biotechnology Inc., $71.6M
- GANX – Gain Therapeutics Inc, $71.6M
- VRCA – Verrica Pharmaceuticals Inc, $70.6M
- APLM – Apollomics Inc. Class A Ordinary Shares, $67.8M
- CSBR – Champions Oncology Inc, $66.9M
- XBIT – XBiotech Inc, $65.9M
- HYFT – ImmunoPrecise Antibodies Ltd., $60.8M
- PLRX – Pliant Therapeutics Inc, $54.7M
- SER – Serina Therapeutics Inc, $45.5M
- DWTX – Dogwood Therapeutics, Inc., $42.5M
- ANVS – Annovis Bio Inc, $42.3M
- ALDX – Aldeyra The, $42.2M
- HBIO – Harvard Bioscience Inc, $37.5M
- EVAX – Evaxion Biotech AS, $36.5M
- IBO – Impact BioMedical, Inc., $34M
- EYPT – EyePoint, Inc, $34M
- NXTC – NextCure Inc, $24.9M
- SHPH – Shuttle Pharmaceuticals Inc, $24.2M
- BYSI – BeyondSpring Inc, $23M
- COCP – Cocrystal Pharma Inc, $20.8M
- ATYR – aTyr Pharma, Inc., $16.8M
- KTTA – Pasithea Therapeutics Corp, $14M
- PTN – Palatin Technologies, Inc. Common Stock, $9.9M
- LTRN – Lantern Pharma Inc, $9.6M
- BFRG – Bullfrog AI Holdings, Inc. Common Stock, $9.5M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- CUBT – Curative Biotechnology Inc, $8.4M
- CURX – Curanex Pharmaceuticals Inc Common Stock, $7.5M
- ACXP – Acurx Pharmaceuticals LLC, $7.2M
- LNAI – Lunai Bioworks Inc., $6.3M
- ENVB – Enveric Biosciences Inc, $6.2M
- EVGN – Evogene, $6.1M
- TRAW – Traws Pharma Inc, $5.7M
- ADXN – Addex Therapeutics Ltd, $5.4M
- PPCB – Propanc Biopharma, Inc. Common Stock, $4.8M
- SCNX – Scienture Holdings, Inc., $4.5M
- VCNX – Vaccinex Inc, $2.8M
- VIVS – VivoSim Labs, Inc., $2.6M
- SPRC – Scisparc Ltd, $2.6M
- BCAB – Bioatla Inc, $2.5M
- BTAI – BioXcel Therapeutics Inc, $2.3M
- KAPA – Kairos Pharma, Ltd., $2M
- MTNB – Matinas BioPharma Holdings Inc, $1.7M
- BDRX – Biodexa Pharmaceticals, $860,974
- ZVSA – ZyVersa Therapeutics Inc., $647,673
- TRVN – Trevena Inc, $57,010
- PBLA – Panbela Therapeutics Inc, $14,564
- BPTH – Bio Path Holdings Inc, $10,059
- STAB – Statera Biopharma Inc, $7,141
- LIPO – Lipella Pharmaceuticals Inc. Common Stock, $2,310
- CALA – Calithera Biosciences Inc, $487
- DICE – Dice Molecules Holdings LLC